Concord Medical Services Holdings Limited reported total net revenues of RMB200.6 million (US$28.0 million) for the first half of 2025, reflecting an 8.3% decrease compared to RMB218.8 million in the same period of 2024. The hospital business recorded net revenues of RMB153.0 million (US$21.4 million), up 11.1% from RMB137.8 million in the first half of 2024, primarily attributed to the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital. The network business reported net revenues of RMB47.6 million (US$6.6 million), down 41.3% from RMB81.0 million in the prior-year period, mainly due to decreased demand for medical equipment and software. Gross loss from operating business amounted to RMB4.3 million (US$0.6 million), compared to RMB41.6 million in the first half of 2024. The gross loss margin was 2.1%, compared to 19.0% in the same period last year, which the company attributed to changes in revenue structure and efficiency improvements related to the launch of proton therapy services. The company highlighted the expansion of its hospital business and the start of proton therapy operations at Guangzhou Concord Cancer Hospital as significant operational developments during the reporting period.